Molecular Basis of Pulmonary Hypertension
Ambrin Farizah Babua*
aMolecular Life Sciences, University of Lausanne, Switzerland.
Pulmonary hypertension is a life threatening incurable disorder. The advances in physiology, genetics, and molecular biology have greatly improved our understanding of the cellular and molecular mechanisms underlying the disorder. In this review, the recent progresses in the understanding of molecular mechanism are presented. Many studies show that pulmonary hypertension is caused due to mitochondrial dysfunction, endothelin-1, prostacyclin and serotonin. These findings and their exploitation will hold promise to find novel treatment options for patients.
Keywords: Molecular mechanism, Pulmonary Hypertension, Mitochondrial dysfunction, Endothelin – 1, Prostacyclin, Serotonin.
Pulmonary hypertension (PH) is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. It reflects the pressure the heart must exert to pump blood from the heart through the arteries of the lungs. This is in contrast with the systemic blood pressure (commonly known as blood pressure, high blood pressure or hypertension) which measures the pressure in the brachial artery while the left side of the heart pumps oxygen-rich blood from the lungs into the rest of the body, measured with a traditional arm cuff 1. The symptoms of the disease include irregular heartbeat, racing pulse, passing out or dizziness, progressive shortness of breath during exercise or activity, and difficulty breathing at rest 2. The classification of PH and their causes are shown in Table 1.
PH is clinically diagnosed when mean pulmonary artery pressure is greater than 25 mm Hg at rest or 30 mm Hg during exercise. It is characterized by an increase in pulmonary vascular resistance that ultimately leads to right-heart failure and death. Although it is a rare disease, it is a progressive and often a fatal lung disorder for which there is no cure3.
This review focusses on some recent studies of the molecular causes of PH. A greater understanding of the cellular and molecular biology of the disease may provide a useful platform to devise novel treatment options for patients.
Mitochondria play an important role in disease pathogenesis. Iqbal et al., 20014 hypothesised that mitochondrial dysfunction contributes to pulmonary hypertension. Mitochondria, despite being a major site of cellular oxygen consumption, are also a major site of cellular oxidative stress. This is due to the generation of reactive oxygen species (ROS), which can thereby contribute to oxidative stress observed with pulmonary hypertension5,6,7,8 . Rather than being completely reduced to water, it has been estimated that 1 to 4% of oxygen consumed by mitochondria is incompletely reduced to ROS (e.g., O2 − and H2O2) due to leakage of electrons from the respiratory chain9,10.
Thus, due to the great demand that is placed on mitochondria to support the rapid rates of growth, combined with the propensity of mitochondria to produce ROS, mitochondria may be extremely important in contributing to oxidative stress associated with pulmonary hypertension.4
The tissues and organs affected by pulmonary hypertension were found to share a common metabolic anomaly linked to mitochondrial dysfunction: the suppression of the mitochondrial glucose oxidation (process through which sugar glucose is converted into energy) and a subsequent increase in cytoplasmic glycolysis. In this sense, the authors suggest that the increase in mitochondrial glucose oxidation may improve PAH pathogenesis. In fact, it has been shown that treatment with dichloroacetate or trimetazidine (both drugs that stimulate glucose oxidation) can improve the right-ventricular function, which is the most important predictive factor for PAH11.
Prostacyclin belongs to the endogenous prostanoids family. It is produced from arachidonic acid in a multistep process involving the enzymes prostacyclin synthase and cyclooxygenase (COX) 12,13,14. In the pulmonary circulation, prostacyclin is released by endothelial cells in the pulmonary artery 15.
Prostacyclin synthesis is decreased in endothelial cells from PAH patients. Analysis of urinary metabolites of prostacyclin showed a decrease in the amount of excreted 6-ketoprostaglandin F1α, a stable metabolite of prostacyclin, in patients with idiopathic PAH 16. Moreover, pulmonary endothelial cells of PAH patients are characterized by reduced expression of prostacyclin synthase 17, and prostacyclin therapy has been shown to improve hemodynamics, clinical status, and survival of patients displaying severe PAH18.
Endothelin-1 (ET-1) is a peptide isolated from vascular endothelial cells. It has the most potent vasoconstricting activity and is also a mitogen for smooth-muscle cells in vitro 19,20. It is found to be elevated in heart failure states as well as in pulmonary arterial hypertension (PAH). The pulmonary production of ET-1 may contribute to the vascular abnormalities associated with PH21. Patients with PH have significantly higher plasma ET-1 concentrations than healthy controls 22,23. Hence ET-1 receptor blockade could be used for treatment.
Nitric oxide is a low molecular weight, oleophilic, very fast reacting endogenous free radical. It is a vasodilator and can inhibit platelet aggregation, thrombosis, and remodelling 24. It is capable of modulating vascular injury and interrupting the elevation of pulmonary vascular resistance selectively. However, it can also produce cytotoxic oxygen radicals and exert cytotoxic and antiplatelet effects. The balance between the protective and adverse effects of nitric oxide is determined by the relative amount of nitric oxide and reactive radicals. Nitric oxide has been shown to be clinically effective in the treatment of pulmonary hypertension and other heart diseases. Additionally, new therapeutic modalities for the treatment of pulmonary hypertension, phosphodiesterase inhibitors, natriuretic peptides and aqueous nitric oxide are also effective for treatment of elevated pulmonary vascular resistance25.
Serotonin, also known as 5-hydroxytryptamine, is a mitogen secreted from neuroendocrine cells in the gut, and carcinoid tumours are a source of increased production 26,27. Serotonin from the gastrointestinal tract is normally metabolised by the liver before it reaches the lungs, and it is also effectively removed by the lungs. Both these organs usually localise the effects of serotonin to the circulation of origin, except when abnormal channels of communication exist, as in portal hypertension, or when metabolic capacity is overwhelmed. Lack of removal of vasoactive substances by the liver could help to explain the association between pulmonary hypertension, portal hypertension, and liver diseases. 28,29
On a molar basis, serotonin is the most potent pulmonary vasoconstrictor identified to date in humans 30, but in the systemic vasculature it causes profound vasodilation 31. These differing effects on the two circulations are similar to those of hypoxaemia and the effects of serotonin are intensified under hypoxaemic conditions and by the administration of catecholamines.
The vascular adverse effects of serotonergic amines such as ergotamine are exacerbated in liver disease 32. The ability of the endothelial cells of the lungs to metabolise amines may also be reduced in disease states, probably because of impairment of amine oxidase enzymes33,34. Such impairment results in raised circulating amine levels, which may provide early evidence of endothelial dysfunction in pulmonary hypertension before morphological changes are apparent.
Table 1: Classification and causes of PH35
Group 1 Pulmonary Arterial Hypertension
• No known cause : Idiopathic (IPAH)
• Inherited : Heritable (HPAH)
• Caused by drugs/toxins
• Caused by conditions(APAH): HIV, Liver disease etc.,
Group 2 Pulmonary Hypertension
• PH with left heart disease
• Caused by conditions that affect the left side of the heart: Mitral valve disease, High blood pressure
Group 3 Pulmonary Hypertension
• PH associated with lung diseases : COPD, Interstitial lung disease
Group 4 Pulmonary Hypertension
• Caused by blood clots in the lungs
• Caused by blood clotting disorders
Group 5 Pulmonary Hypertension
· Caused by unclear multifactorial mechanisms:
· Blood disorders
· System disorders
· Metabolic disorders
· Other conditions like tumor
A great progress has been made in the identification and the understanding of the molecular basis of PH. However, we are still far away from a comprehensive understanding of this deadly disease. This is true for the proliferative abnormalities of the pulmonary vasculature and is even truer for the pathogenetic sequelae underlying right ventricular hypertrophy and failure 36. There is a need for a greater understanding of the mechanisms of PH. This would, in the future, yield improved treatments options for patients.
- Iqbal,M.,D,Cawthon, R.F.Wideman,Jr., and W.G.Bottje, Lung mitochondrial dysfunction in pulmonary hypertension syndrome. I. Site-specific defects in electron transport chain. Poultry Sci. 2001; 80:485-495.
- Enkvetchakul, B., W. Bottje, N. Anthony, R. Moore, and W. Huff, Compromised antioxidant status associated with ascites in broilers. Poultry Sci. 1993; 72:2272–2280.
- Bottje, W. G., and R. F. Wideman, Jr., Potential role of free radicals in the etiology of pulmonary hypertension syndrome. Poult. Avian Biol. Rev. 1995; 6:211–231.
- Bottje, W. G., B. Enkvetchakul, R. Moore, and R. McNew, Effect of α-tocopherol on antioxidants, lipid peroxidation, and the incidence of pulmonary hypertension syndrome (ascites) in broilers. Poultry Sci. 1995;74:1356–1369.
- Diaz-Cruz, A., C. Nava, R. Villanueva, M. Serret, R. Guinzberg, and E. Pina, Hepatic and cardiac oxidative stress and other metabolic changes in broilers with the ascites syndrome. Poultry Sci. 1996; 75:900–903.
- Chance, B., H. Sies, and A. Boveris, Hydroperoxide metabolism in mammalian organs. Physiol. Rev. 1979; 59:527–605.
- Boveris, A., and B. Chance, The mitochondrial generation of hydrogen peroxide. Biochem. J. 1973; 134:707–711.
- Deng H, Wu J, So SP, Ruan KH. Identification of the residues in the helix F/G loop important to catalytic function of membrane-bound prostacyclin synthase. Biochemistry 2003; 42(19):5609–17.
- Ruan KH. Advance in understanding the biosynthesis of prostacyclin and thromboxane A2 in the endoplasmic reticulum membrane via the cyclooxygenase pathway. Mini Rev Med Chem 2004;4(6):639–47.
- Lin Y, Wu KK, Ruan KH. Characterization of the secondary structure and membrane interaction of the putative membrane anchor domains of prostaglandin I2 synthase and cytochrome P450 2C1. Arch Biochem Biophys 1998;352(1):78–84.
- Ruan KH, Wu J, Cervantes V. Characterization of the substrate mimic bound to engineered prostacyclin synthase in solution using high-resolution NMR spectroscopy and mutagenesis: implication of the molecular mechanism in biosynthesis of prostacyclin. Biochemistry 2008;47(2):680–8.
- Christman B.W, McPherson C.D, Newman J.H; An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992;327:70-75.
- Tuder R.M, Cool C.D, Geraci M.W; Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 1999;159 ,1925-1932.
- Marc Humbert, Nicholas W Morrell, Stephen L Archer, Kurt R Stenmark, Margaret R MacLean, Irene M Lang, Brian W Christman, E.Kenneth Weir, Oliver Eickelberg, Norbert F Voelkel, Marlene Rabinovitch, Cellular and molecular pathobiology of pulmonary arterial hypertension, Journal of the American College of Cardiology, 2004;43(12),13-24,
- Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature1988;332:411–415.CrossRefMedlineWeb of Science
- Komuro I, Kurihara H, Sugiyam T, Takaku F, Yazaki YEndothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett 1988;238:249–252.CrossRefMedlineWeb of Science
- Patrice Cacoub, Richard Dorent, Patrick Nataf, Alain Carayon, Marc Riquet, Eric Noe, Jean Charles Piette, Pierre Godeau, Iradj Gandjbakhch ,Endothelin-1 in the lungs of patients with pulmonary hypertension. Cardiovascular Research 1997; 33 (1) 196-200; DOI: 10.1016/S0008-6363(96)00189-7
- Cacoub P, Dorent R, Maistre G, et al. Endothelin-1 in primary pulmonary hypertension and the Eisenmenger syndrome. Am J Cardiol,1993;71:448–450.CrossRefMedlineWeb of Science
- Stewart DJ, Levy RD, Cernacek P, Langleben D,Increased plasma endothelin-1 in pulmonary hypertension:marker or mediator of disease. Ann Intern Med,1991; 114:464–469.
- Cooke JP, Dzau VJ, Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 1997;48:489–509.
- Sim J-Y. Nitric oxide and pulmonary hypertension. Korean Journal of Anesthesiology. 2010;58(1):4-14. doi:10.4097/kjae.2010.58.1.4.
- Perry RR, Vinik AI ,Endocrine tumors of the GI tract. Annu Rev Med, 1996; 47:59–62,29.
- Hart CM, Block ER , Lung serotonin metabolism. Clin Chest Med, 1989; 10:59–70.
- Lockhart A, Pulmonary arterial hypertension in portal hypertension. Clin Gastroenterol 1985;14:123–138.
- Mandell MS, Groves BM ,Pulmonary hypertension in chronic liver disease. Clin Chest Med, 1996; 17:17–33.
- Heffner JE, Sahn SA, Repine JE , The role of platelets in the adult respiratory distress syndrome. Culprits or bystanders? Am Rev Respir Dis, 1987; 135:482–492.
- Comroe JH, van Lingen B, Stroud RC, Reflex and direct cardiopulmonary effects of 5 OH tryptamine (serotonin). Their possible role in pulmonary embolism and coronary thrombosis. Am J Physiol, 1953;173:379–386.
- Katz AI, Massry SG, Tikvah P Arteriospasm after ergotamine tartrate in infectious hepatitis. Arch Intern Med, 1966;118:62–64.
- Block ER, Stalcup A, Metabolic functions of the lung. Of what clinical relevance? Chest, 1982; 81:215–223.
- Boor PJ, Hysmith RM, Sanduja R, A role for a new vascular enzyme in the metabolism of xenobiotic amines. Circ Res 1990; 66:249–252.
- Seeger W, Pullamsetti SS. Mechanics and mechanisms of pulmonary hypertension—Conference summary and translational perspectives. Pulmonary Circulation. 2013; 3(1):128-136.